CD8A and neoplasm: Agonistic anti-CD40 cross-linking antibody fully restored CD8+ T cell-mediated tumor rejection in the complete absence of CD4+ T cells (Figure 11A), suggesting that providing Th1-based cell help is a key feature for effective therapy even in the absence of CD4+ Tfh.